GWM
AZN icon

Geneos Wealth Management’s AstraZeneca AZN Stock Holding History

Geneos Wealth Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,949
Closed -$7.53M – 2474
2025
Q4 		$7.53M Sell
40,949
-346
-0.8% -$60.7K 0.18% 140
2025
Q3 		$6.34M Buy
41,295
+2,697
+7% +$408K 0.16% 160
2025
Q2 		$5.39M Buy
38,598
+19,168
+99% +$2.69M 0.13% 192
2025
Q1 		$2.86M Buy
19,430
+11,401
+142% +$1.65M 0.04% 407
2024
Q4 		$1.05M Sell
8,029
-168
-2% -$23.5K 0.04% 413
2024
Q3 		$1.28M Buy
8,197
+833
+11% +$134K 0.05% 356
2024
Q2 		$1.15M Sell
7,364
-97
-1% -$14.6K 0.05% 339
2024
Q1 		$1.01M Buy
7,461
+2,286
+44% +$303K 0.05% 345
2023
Q4 		$697K Sell
5,175
-455
-8% -$59.1K 0.03% 398
2023
Q3 		$763K Sell
5,630
-372
-6% -$50.8K 0.04% 368
2023
Q2 		$859K Buy
6,002
+263
+5% +$38.7K 0.05% 342
2023
Q1 		$797K Sell
5,739
-712
-11% -$95.8K 0.05% 344
2022
Q4 		$875K Sell
6,451
-151
-2% -$18.9K 0.05% 299
2022
Q3 		$724K Buy
6,602
+116
+2% +$14.7K 0.05% 314
2022
Q2 		$855K Sell
6,486
-220
-3% -$28.9K 0.04% 362
2022
Q1 		$889K Sell
6,706
-418
-6% -$50.1K 0.04% 387
2021
Q4 		$829K Buy
7,124
+877
+14% +$103K 0.03% 451
2021
Q3 		$745K Buy
6,247
+24
+0.4% +$2.79K 0.03% 469
2021
Q2 		$756K Buy
6,223
+3,621
+139% +$397K 0.03% 449
2021
Q1 		$276K Sell
2,602
-857
-25% -$86.2K 0.01% 838
2020
Q4 		$304K Buy
3,459
+1,939
+128% +$205K 0.01% 670
2020
Q3 		$168K Buy
1,520
+312
+26% +$34.7K 0.01% 739
2020
Q2 		$127K Sell
1,208
-166
-12% -$17.1K 0.01% 813
2020
Q1 		$116K Sell
1,374
-207
-13% -$19.5K 0.01% 791
2019
Q4 		$159K Buy
1,581
+82
+5% +$7.72K 0.01% 785
2019
Q3 		$135K Hold
1,499
– – 0.01% 786
2019
Q2 		$123K Buy
1,499
+125
+9% +$9.8K 0.01% 831
2019
Q1 		$111K Buy
1,374
+166
+14% +$13.1K 0.01% 826
2018
Q4 		$91K Sell
1,208
-92
-7% -$7.18K 0.01% 866
2018
Q3 		$102K Sell
1,300
-168
-11% -$12.7K 0.01% 872
2018
Q2 		$103K Hold
1,468
– – 0.01% 777
2018
Q1 		$102K Sell
1,468
-496
-25% -$34.4K 0.01% 743
2017
Q4 		$136K Buy
1,964
+348
+22% +$23.5K 0.01% 650
2017
Q3 		$109K Buy
1,616
+150
+10% +$9.48K 0.01% 673
2017
Q2 		$99K Sell
1,466
-664
-31% -$43.4K 0.01% 679
2017
Q1 		$132K Sell
2,130
-45,442
-96% -$2.65M 0.01% 586
2016
Q4 		$2.6M Buy
47,572
+22,931
+93% +$1.3M 0.34% 82
2016
Q3 		$1.63M Buy
24,641
+15,350
+165% +$1M 0.22% 111
2016
Q2 		$565K Buy
9,291
+3,975
+75% +$231K 0.08% 224
2016
Q1 		$300K Buy
+5,316
New +$319K 0.05% 336

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Geneos Wealth Management's AZN Position: Q1 2026 in Review

Geneos Wealth Management sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 40,949 shares — an estimated $7.53M sold.

Geneos Wealth Management first reported a position in AZN in Q1 2016 and held it in 40 quarters. The position peaked at $7.53M in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Geneos Wealth Management reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Geneos Wealth Management sold 40,949 AstraZeneca shares in Q1 2026, an estimated $7.53M.
  • Geneos Wealth Management first reported a position in AstraZeneca in Q1 2016 and held it in 40 quarters.
  • Geneos Wealth Management's AstraZeneca position peaked at $7.53M in Q4 2025.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Geneos Wealth Management's 13F filing for Q1 2026, filed 5 May 2026.